Immucor Message Board - Msg: 8506281

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Immucor

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Jim Cash who wrote (300)	3/24/1999 8:55:00 PM
From: Thomas Kirwin	of 422

EPS - Downward Revision I've revised my personal eps guesstimate downward based on the lack of sales information available from the company. This conservatism may be unfounded. It is nearly impossible construct an accurate pro-forma based on the information available today. The revision reflects the absence of data and updated facts regarding instrument/reagent sales. Given the above, I suspect that Immucor's 3rd quarter eps ended February 28th will be $0.11 - $0.12. Earnings in this range would be fantastic as it would represent nearly 100% growth. Background Immucor reported fully diluted earnings per share of $0.09 during the second quarter versus $0.06 last year. Adjusted for one-time charges related to the Gamma acquisition, second quarter earnings per share would have been $0.12. Regards, Tom

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next